Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2006

View Archived Issues

AP-5346 shows different kinetics and preclinical activity than oxaliplatin

Update on lacosamide at American Pain Society

Use of alvimopan for the gastrointestinal adverse effects of opioids studied

Q1 highlights at Schering-Plough

Novartis makes positive start to year

BioProgress and Uluru to develop antiemetic product

ALGRX-3268 local analgesia effective in children

Phase II studies show reduced pain with ALGRX-4975 in lateral epicondylitis, neuroma

Update on the antiatherosclerotic effects of D-4F

Oral RSD-1235 shows no significant effect on QT interval in healthy volunteers

ACR-16 improves Huntington's disease symptoms in phase II study

Cytogen enters into Quadramet royalty buyout agreement with Berlex

Roche to acquire trimeric Apo A-I compound from Borean Pharma

Phase I/II trial studying Lovaxin C to treat cervical cancer

VQD-002 IND accepted by FDA

Tindamax completes phase III trial for bacterial vaginosis

Femara recommended for use in Scotland

Pfizer and Monogram Biosciences collaborate on HIV Co-Receptor Tropism Assay

Hana completes licensing of three targeted cancer compounds from Inex

Eisai plans phase I study for E-2012 for Alzheimer's disease

Silicon phthalocyanine Pc 4 safe in ongoing phase I study in skin conditions

SGN-30 induces responses in cutaneous anaplastic large cell lymphoma patients

New coagulation factor Xa inhibitors emerge from Bristol-Myers Squibb R&D

Recent Sankyo and Inotek patents describe new treatments for cardiovascular diseases

Bayer patent describes therapeutic agents for urinary incontinence

Canadian approval for Velcade in second-line approval for multiple myeloma

Xcytrin NDA to be filed by year-end

Lilly seeks approval of Cymbalta for generalized anxiety disorder

Plavix launched in Japan

Opticin may contribute to the antiangiogenic properties of the vitreous humor

New intraocular delivery system of antiproliferative agents reported

A novel multitargeted tyrosine kinase prodrug proves beneficial for CNV disorders

Novel neuroprotective strategies in glaucoma therapeutics - Part II

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...